Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial; Hans C. Lee; Ashraf Badros; Suzanne Trudel; Ajay K. Nooka; Ajai Chari; Al‐Ola Abdallah; Natalie S. Callander; Nikoletta Lendvai; Douglas W. Sborov; Attaya Suvannasankha; Katja Weisel; Lionel Karlin; Edward N. Libby; Bertrand Arnulf; Thierry Façon; Cyrille Hulin; K. Martin Kortüm; Paula Rodríguez‐Otero; Saad Z. Usmani; Parameswaran Hari; Rachid Baz; Hang Quach; Philippe Moreau; Peter M. Voorhees; Ira Gupta; Axel Hoos; Eric Zhi; January Baron; Trisha Piontek; Eric Lewis; Roxanne C. Jewell; Elisha J. Dettman; Rakesh Popat; Simona Degli Esposti; Joanna Opalinska; Paul G. Richardson; Adam D. Cohen

doi:10.1016/s1470-2045(19)30788-0

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial(Winship Cancer Institute), Hans C. Lee(The University of Texas MD Anderson Cancer Center), Ashraf Badros(University of Maryland, Baltimore), Suzanne Trudel(Princess Margaret Cancer Centre), Ajay K. Nooka(Emory University), Ajai Chari(Icahn School of Medicine at Mount Sinai), Al‐Ola Abdallah(The University of Kansas Cancer Center), Natalie S. Callander(University of Wisconsin Carbone Cancer Center), Nikoletta Lendvai(Memorial Sloan Kettering Cancer Center), Douglas W. Sborov(University of Utah), Attaya Suvannasankha(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Katja Weisel(University of Tübingen), Lionel Karlin(Hospices Civils de Lyon), Edward N. Libby(University of Washington Medical Center), Bertrand Arnulf(Assistance Publique – Hôpitaux de Paris), Thierry Façon(Centre Hospitalier Universitaire de Lille), Cyrille Hulin(Centre Hospitalier Universitaire de Bordeaux), K. Martin Kortüm(Universitätsklinikum Würzburg), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Saad Z. Usmani(Levine Cancer Institute), Parameswaran Hari(Medical College of Wisconsin), Rachid Baz(Moffitt Cancer Center), Hang Quach(University of Melbourne), Philippe Moreau(Centre Hospitalier Universitaire de Nantes), Peter M. Voorhees(Levine Cancer Institute), Ira Gupta(GlaxoSmithKline (United States)), Axel Hoos(GlaxoSmithKline (United States)), Eric Zhi(GlaxoSmithKline (United States)), January Baron(GlaxoSmithKline (United States)), Trisha Piontek(GlaxoSmithKline (United States)), Eric Lewis(Research Triangle Park Foundation), Roxanne C. Jewell(Research Triangle Park Foundation), Elisha J. Dettman(GlaxoSmithKline (United States)), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Simona Degli Esposti(Moorfields Eye Hospital NHS Foundation Trust), Joanna Opalinska(GlaxoSmithKline (United States)), Paul G. Richardson(Dana-Farber Cancer Institute), Adam D. Cohen(Sidney Kimmel Cancer Center)

The Lancet Oncology

December 16, 2019

10.1016/s1470-2045(19)30788-0

Cited by 791

Abstract

Related Papers

No related papers found

Powered by citation graph analysis